SHPH (Shuttle Pharmaceuticals Holdings) EPS without NRI: $-62.13 (TTM As of Mar. 2026)


SHPH Shuttle Pharmaceuticals Holdings Inc SHPH
24 GF Score
Price $3.58
! 1 Warning Sign
View Full Analysis

What is Shuttle Pharmaceuticals Holdings EPS without NRI?

Shuttle Pharmaceuticals Holdings SHPH +8.22% 24 EPS without NRI is $-62.13 as of Mar. 2026. GuruFocus rates SHPH with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 787 Drug Manufacturers companies, Shuttle Pharmaceuticals Holdings ranks better than 89.71% on this metric.

Shuttle Pharmaceuticals Holdings's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-4.45. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-62.13.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 56.50% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -6.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Shuttle Pharmaceuticals Holdings's EPS without NRI or its related term are showing as below:

SHPH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -125.5   Med: -43.9   Max: 56.5
Current: 56.5

During the past 6 years, Shuttle Pharmaceuticals Holdings's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 56.50% per year. The lowest was -125.50% per year. And the median was -43.90% per year.

SHPH's 3-Year EPS without NRI Growth Rate is ranked better than
89.71% of 787 companies
in the Drug Manufacturers industry
Industry Median: 9.7 vs SHPH: 56.50

Shuttle Pharmaceuticals Holdings's EPS (Diluted) for the three months ended in Mar. 2026 was $-4.30. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-60.62.

Shuttle Pharmaceuticals Holdings's EPS (Basic) for the three months ended in Mar. 2026 was $-4.30. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-60.62.


Shuttle Pharmaceuticals Holdings  (NAS:SHPH) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Shuttle Pharmaceuticals Holdings EPS without NRI Related Terms


Shuttle Pharmaceuticals Holdings EPS without NRI Historical Data

* Premium members only.

The historical data trend for Shuttle Pharmaceuticals Holdings's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shuttle Pharmaceuticals Holdings EPS without NRI Chart

Shuttle Pharmaceuticals Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial -270.11 -889.60 -1,125.74 -804.43 -73.24

Shuttle Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.07 -33.00 -10.51 -14.17 -4.45

SHPH vs UPC, CBIH, CPMD: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shuttle Pharmaceuticals Holdings PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Shuttle Pharmaceuticals Holdings's PE Ratio without NRI falls into.


SHPH
24GF Score
Shuttle Pharmaceuticals Holdings Inc SHPH
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shuttle Pharmaceuticals Holdings EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-62.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-62.13 mean?
Shuttle Pharmaceuticals Holdings (SHPH) has a EPS without NRI of $-62.13 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #81 out of 787 companies in the Drug Manufacturers industry, placing it in the top 10.3%.
Is Shuttle Pharmaceuticals Holdings' EPS without NRI too high?
Shuttle Pharmaceuticals Holdings' current EPS without NRI is $-62.13. Based on the distribution chart, Shuttle Pharmaceuticals Holdings ranks #81 out of 787 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shuttle Pharmaceuticals Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Shuttle Pharmaceuticals Holdings' EPS without NRI compare to UPC and CBIH?
According to the Drug Manufacturers industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #81 out of 787 companies for EPS without NRI. This places Shuttle Pharmaceuticals Holdings in the top 10% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shuttle Pharmaceuticals Holdings's current EPS without NRI is $-62.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shuttle Pharmaceuticals Holdings stock overvalued right now?
Shuttle Pharmaceuticals Holdings (SHPH) has a current EPS without NRI of $-62.13. The current EPS without NRI is $-62.13. Shuttle Pharmaceuticals Holdings' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Shuttle Pharmaceuticals Holdings (SHPH), the current EPS without NRI is $-62.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shuttle Pharmaceuticals Holdings Business Description

Address 401 Professional Drive, Suite 260, Gaithersburg, MD, USA, 20879
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
24GF Score

Get the complete analysis for SHPH

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.58
Price